Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

V Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

Non-GAAP Financial Measures This press release provides financial measures for net revenue, cost of sales, gross margin, net loss and basic and diluted loss per share that exclude specifically identified non-routine items, and are therefore not calculated in accordance with accounting principles generally accepted in the United States ("GAAP"). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance that enhances management's and investors' ability to evaluate and compare Cadence's operating results.

These non-GAAP financial measures are not intended to be used in isolation and should not be considered a substitute for any other performance measure determined in accordance with GAAP. Investors and potential investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool, including that other companies may calculate similar non-GAAP financial measures differently than Cadence, limiting their usefulness as a comparative tool. Cadence compensates for these limitations by providing specific information regarding the GAAP amount excluded from the non-GAAP financial measures. Cadence further compensates for the limitations of its use of non-GAAP financial measures by presenting comparable GAAP measures more prominently. Investors and potential investors are encouraged to review the calculation of non-GAAP financial measures contained within this press release with Cadence's GAAP net income and basic and diluted loss per share.

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... in product development and promotion has led to ... This mistrust, fueled by concerns about the insidious ... fed by reports of spectacular fines to the ... of industry suppression of negative clinical trial results, ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ... patient safety, clinical outcomes, and medication adherence. , ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ... Brown, SPIE Senior Director for Global Business Development. ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... Plague.” In this time period, doctors did not know ... at times, to the death of vulnerable patients. In ... don’t know that they may be unwittingly transmitting herpes ... study showed that severe fatigue contributed to latent herpes ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... (OTC Bulletin Board: MNCN), an innovative, global wellness solutions company, ... the OTC Bulletin Board under the symbol "MNCN." The Company,s ... , "The move to the OTC Bulletin Board will ... investors and help improve our trading liquidity," said Patrick Sheridan, ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced today that it has received a European ... technology for the improved oral delivery of drugs. ... Reverse Micelle Compositions and Uses Thereof" covers lipid ...
... July 8 iZumi Bio, Inc. and Pierian, Inc. ... company, iPierian, Inc. Building on the iZumi infrastructure and ... cellular reprogramming to change the paradigm of drug discovery. ... development of new therapeutics using induced pluripotent stem (iPS) ...
Cached Biology Technology:DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 2DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 3DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 2iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 3iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 4iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 6
(Date:4/15/2014)... The global experts who study the deadliest infectious ... Thomas G. Ksiazek, professors at the University of Texas ... 6th annual International Symposium on Filoviruses. The filoviruses include ... to 90 percent of people infected. The current outbreak ... more than 100 deaths so far. , "This ...
(Date:4/15/2014)... 2014) The American Association of Anatomists (AAA) is ... awards will be presented during the Closing Awards Ceremony ... Tuesday, April 29th at 7:30 p.m. during AAA,s 2014 ... The 2014 award winners are: , Henry ... the Icahn School of Medicine at Mount Sinai, Past-President ...
(Date:4/15/2014)... deforestation could cause temperatures in the Congo Basin ... intensify warming caused by greenhouse gases by half, ... University of Leuven, Belgium. , Explosive population growth ... of tropical rainforests in Central Africa. A team ... how these practices will affect longer-term temperatures in ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3American Association of Anatomists 2014 award winners 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... in German . , Innovations relating to mobility, ... KIT at the 2011 Hannover Messe from April 4 ... present a hybrid Porsche racing car, developments in battery research, ... a European energy supply system, and the Energy Solution Center ...
... the key to creating cyborg interfaces? Circuitry that links human ... as a robotic limb or artificial eye might one day ... Writing in the International Journal of Medical Engineering and ... can be made using human blood. Memristors were a theoretical ...
... that allow facilities to buy and sell emission allowances ... in the U.S. two decades ago. But critics worry ... low-income and minority communities. A new study ... of Public and Environmental Affairs, finds the problem hasn,t ...
Cached Biology News:KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5Blood simple circuitry for cyborgs 2Study: Emissions trading doesn't cause pollution 'hot spots' 2Study: Emissions trading doesn't cause pollution 'hot spots' 3
Human ABCG2 MAb (Clone 5D3)...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... Engineered with new technology incorporating the ... unsurpassed flexibility, the new Varian NMR ... spectrometer available today., ,The Varian NMR ... transmitter and receiver channel, providing pulse ...
Biology Products: